SCHEMBL3201563

SCHEMBL3201563

CNC(=O)C(O)C(c1ccccc1)N(C)c1cccc2ccccc12

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 7/20 0.64
SLC6A4 P31645 7/20 0.64
SIGMAR1 Q99720 2/20 0.40
PLK1 P53350 1/20 0.39
ALDH1A1 P00352 3/20 0.37
KDM4E B2RXH2 2/20 0.37
GAA P10253 2/20 0.37
MAPT P10636 2/20 0.37
RAB9A P51151 2/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
NOX1 Q9Y5S8 1/20 0.37
LMNA P02545 2/20 0.37
PGR P06401 1/20 0.37
PTGS1 P23219 1/20 0.37
MAPK1 P28482 1/20 0.37
HSD17B10 Q99714 1/20 0.37
TACR3 P29371 1/20 0.37
MMP9 P14780 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3200649 0.87 SLC6A2 (0.62) SLC6A2SLC6A4SIGMAR1ALDH1A1
SCHEMBL3201224 0.83 SLC6A2 (0.61) SLC6A2SLC6A4ALDH1A1LMNA
SCHEMBL3207957 0.82 SLC6A2 (0.62) SLC6A2SLC6A4ALDH1A1KDM4EGAA
SCHEMBL3201209 0.79 SLC6A2 (0.57) SLC6A2SLC6A4LMNA
SCHEMBL3201198 0.79 SLC6A2 (0.57) SLC6A2SLC6A4LMNA
SCHEMBL13422586 0.78 SLC6A2 (1.00) SLC6A2SLC6A4
SCHEMBL3198953 0.78 SLC6A2 (1.00) SLC6A2SLC6A4
Hydrochloric Acid SCHEMBL3202292 0.77 SLC6A2 (0.97) SLC6A2SLC6A4
SCHEMBL3191686 0.75 SLC6A2 (0.61) SLC6A2SLC6A4ALDH1A1MAPTMEN1
SCHEMBL3191055 0.74 SLC6A2 (0.64) SLC6A2SLC6A4MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7671238-B2 Arylamino-arylpropanolamine derivatives and methods of their use WYETH LLC (US) 2010-03-02 US disclosed
WO-2008042362-A1 ARYLAMINO-ARYLPROPANOLAMINE DERIVATIVES AND METHODS OF THEIR USE WYETH (US) 2008-04-10 WO disclosed
US-20080085938-A1 Arylamino-Arylpropanolamine Derivatives and Methods of Their Use WYETH (US) 2008-04-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080085938-A1 Arylamino-Arylpropanolamine Derivatives and Methods of Their Use PNMT, PAH, SLC18A2 SLC6A2 4/4885SLC6A4 6/4885SIGMAR1 759/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.